Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Change In Payables And Accrued Expense : HK$0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Change In Payables And Accrued Expense?

Shenzhen Hepalink Pharmaceutical Group Co's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was HK$0 Mil. It means Shenzhen Hepalink Pharmaceutical Group Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2024 to Mar. 2025 .

Shenzhen Hepalink Pharmaceutical Group Co's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was HK$0 Mil. It means Shenzhen Hepalink Pharmaceutical Group Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Shenzhen Hepalink Pharmaceutical Group Co Change In Payables And Accrued Expense Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Change In Payables And Accrued Expense Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Shenzhen Hepalink Pharmaceutical Group Co Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Shenzhen Hepalink Pharmaceutical Group Co Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Change In Payables And Accrued Expense

Traded in Other Exchanges

002399:China

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.

Executives

Hong Ze Jun	2101 Beneficial owner
Orbimed Capital Llc	2102 Investment manager
Morgan Stanley & Co. International Plc	2105 Underwriter
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Avict Global Holdings Limited	2101 Beneficial owner
Worldwide Healthcare Trust Plc	2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co Headlines

No Headlines